Crohn's Disease Eye Problems: Which Are Urgent

Crohn's disease can inflame your eyes, and the important thing to know is that the versions differ enormously in how much they matter. The common one is a red, tender patch on the white of the eye that clears up. The uncommon ones can damage sight, and the most dangerous of them can arrive without pain at all.

Almost every patient-facing page on this subject blurs that difference. They list four or five conditions in a row, note that uveitis is "more serious", and finish with advice to mention it to your doctor. That is not enough to act on at 9pm on a Sunday with one eye aching. This article is built around the triage instead: which symptoms mean get seen, which mean book something, and which mean buy lubricating drops.

Yes, Crohn's can affect your eyes, and one version is a same-day problem

The short version: a patch of redness on the white with normal vision and no real pain is most likely episcleritis, and it usually settles. Deep aching pain, dislike of bright light, blurring, new floaters or flashes, or a red eye that is worsening over days points inside the eye, and that needs looking at quickly.

Eye involvement sits inside a wider category. An extraintestinal manifestation is inflammation driven by inflammatory bowel disease that shows up somewhere other than the bowel, and the classic sites are joints, eyes, skin, mouth and the bile ducts. Our guide to joint pain with Crohn's disease carries the shared explainer of what that category is and which members track bowel activity. There is a dedicated European guideline for the whole group (Gordon 2024), and we should say plainly that no abstract for it is indexed and we could not read the full text, so we cite it only for the fact that dedicated guidance exists, never for what it recommends. This article is about the eye specifically.

In the Swiss IBD cohort of 950 people, uveitis was recorded in 6% of those with Crohn's and 4% of those with ulcerative colitis. In the Crohn's group that put it level with erythema nodosum and ankylosing spondylitis, also 6% each, behind arthritis at 33% and mouth ulcers at 10%, and ahead of psoriasis and pyoderma gangrenosum at 2% (Vavricka 2011). Pages that rank uveitis as "the third most common" manifestation are imposing an order on figures that tie. Narrative reviews put ocular disease third overall among manifestations outside the gut, after musculoskeletal and skin involvement, and note it is more frequent in Crohn's than in colitis (Pytrus 2022).

The five things that get called "a Crohn's eye problem"

They are not variations on one theme. They differ in where the inflammation sits, what it feels like, and what happens if you leave it.

That table is drawn from two narrative reviews that cover the same ground independently (Richardson 2024, Migliorisi 2024). Richardson and colleagues single out peripheral ulcerative keratitis as warranting urgent review because of the risk of corneal perforation, and they are one of the few sources to say so plainly.

The most widely circulated patient leaflet on this topic, the Crohn's & Colitis Foundation's eye complications fact sheet, does not mention scleritis or peripheral ulcerative keratitis at all, and it was last dated January 2015 (Crohn's & Colitis Foundation fact sheet). It is where the frequently quoted "approximately 10% of people with IBD experience eye problems" comes from, and it carries no citation for that figure. We are not criticising the leaflet for existing. We are pointing out that the two genuinely urgent conditions are missing from the page most people land on.

How common is this really? The honest answer is that nobody knows within an order of magnitude

Published prevalence for eye involvement in Crohn's ranges from under 1% to 60%. That is not a biological range. It is four different questions being answered with the same word.

Physician questionnaire, at enrolment. Uveitis in 6% of Crohn's patients (Vavricka 2011).

The same national cohort, twelve years of follow-up. Uveitis in 11.1% of 1,840 Crohn's patients and 5.6% of 1,426 with colitis, odds ratio 2.11 (Biedermann 2019). Same cohort, roughly double the figure, because this one counted anyone who developed uveitis across the follow-up period rather than who had it at one moment.

Eye-specialist-confirmed, from a hospital's whole IBD list. A chart review of 1,320 IBD patients at one American centre found 42 with uveitis, 2 with scleritis and 2 with peripheral ulcerative keratitis: about 3.5% in total, and 3.2% for uveitis alone (Arzbecker 2024).

Everyone gets a full eye examination, everything counts. Twelve of 20 Crohn's patients, 60%, had "ocular involvement" in a Turkish prospective study, alongside 22.9% of 96 colitis patients. But read what was counted: conjunctivitis in 8.6% of the whole group, blepharitis in 6.9%, uveitis in 5.2%, cataract in 5.2%, episcleritis in 3.4% (Yilmaz 2007). Conjunctivitis, lid inflammation and cataract are extremely common in people without IBD. The 60% is real arithmetic on 20 people and it tells you almost nothing about Crohn's-driven eye disease.

Children. A systematic review of 15 studies and 7,467 children put symptomatic ocular manifestations at 0.62% to 1.82%, with Crohn's carrying higher odds than colitis or unclassified IBD, odds ratio 2.70 with a 95% confidence interval of 1.51 to 4.83 (Ottaviano 2018).

The range matters practically, and it comes with a gap worth naming. The only figure in this set where an eye specialist confirmed every diagnosis is 3.2%, and that is for an IBD population as a whole, not broken down by Crohn's and colitis (Arzbecker 2024). The Crohn's-specific figures, 6% and 11.1%, come from physician questionnaires and cohort records rather than confirmed eye examinations (Vavricka 2011, Biedermann 2019). So a specialist-confirmed, Crohn's-specific uveitis rate is a number we did not find published in anything we read. The single-digit range is the right order of magnitude; a precise figure for your condition is not available.

The claim that IBD uveitis is "bilateral and posterior" comes from 17 patients in 1997

This is the most consequential thing on this page, because the characterisation is repeated widely and the better evidence points the other way.

A 1997 comparison of uveitis in IBD against uveitis in spondyloarthropathy found that where the spondyloarthropathy group had anterior, unilateral, sudden and self-limiting disease, the IBD group frequently had uveitis that was bilateral, posterior, insidious in onset or chronic. Eighty-two per cent of the IBD patients were female, 46% were HLA-B27 positive against 89% in the comparison group, and in 59% the uveitis diagnosis came before the IBD diagnosis (Lyons 1997).

Now read the denominators. That study had 17 IBD patients referred to a university uveitis clinic, and only 15 of them had disease type that could be evaluated, so the abstract's percentages move between a base of 17 and a base of 15 within four sentences. It is also, by design, a tertiary referral series: people whose uveitis was straightforward and settled with drops never reach a subspecialty clinic. The proportion who underwent HLA-B27 typing is not stated, so the 46% has no denominator we can check.

Compare the 2024 series, which started from a hospital's 1,320 IBD patients rather than from a uveitis clinic's referrals (Arzbecker 2024). Of 42 uveitis patients, 38 had anterior uveitis, 90.5%. Of those 38, 31 followed an episodic pattern, 81.6%, and 19 were unilateral, 50.0%. Only four of the 42 had posterior segment involvement, 9.5%. Uveitis preceded the IBD diagnosis in 10 patients, not 59%.

So the typical picture is close to the opposite of the classic description: most often front of the eye, most often in episodes, half the time one eye at a time. Both studies are true about the populations they measured. Only one of them describes what a person newly diagnosed with Crohn's is likely to meet.

Does an eye flare mean my gut is flaring?

Usually not, and this is where people get dismissed. The pattern that both major reviews describe is that episcleritis tends to run with bowel disease activity while uveitis does not, and uveitis can arrive before the IBD diagnosis or during a period of good bowel control (Richardson 2024, Pytrus 2022).

That is the reverse of what most patient pages say. The Crohn's & Colitis Foundation fact sheet tells readers "uveitis generally improves when the IBD is brought under control", and a widely read health site states that eye symptoms "often coincide with bowel symptom flare-ups". For episcleritis that is defensible. For uveitis the reviews say the opposite, and the practical consequence of believing the wrong version is that someone with a painful eye and a calm bowel concludes the two cannot be connected.

The threads read exactly as you would predict. In a r/CrohnsDisease thread asking whether anyone else has eye issues, the original poster described months of recurring redness and irritation while their gut symptoms had been controlled for years on a biologic, having been told first that it was conjunctivitis and then allergies before anyone mentioned Crohn's (r/CrohnsDisease thread). Several replies described the same sequence. One described being told by both an ophthalmologist and a rheumatologist that their recurrent iritis and macular swelling had nothing to do with their gut. That is lived experience rather than evidence, but it matches what the reviews would have predicted.

The same pattern shows up in the broader extraintestinal threads, where eye inflammation gets volunteered alongside joints and skin lesions as part of one experience of "it is not just my gut" (r/CrohnsDisease thread).

If you are trying to work out whether your gut is actually active at the same time, our guide to telling whether you are in a Crohn's flare covers what does and does not count, and interpreting a Harvey-Bradshaw Index score explains the bedside score that awards a single point for eye inflammation under its complications item, the same single point it awards for an abscess (Harvey 1980).

The sight-threatening form can creep up on you, and that is the whole problem

Front-of-the-eye inflammation announces itself: red, sore, uncomfortable in bright light. Inflammation further back does not always do that. The referral series that characterised IBD uveitis described it as frequently insidious in onset and chronic in duration rather than sudden and self-limiting (Lyons 1997), and posterior involvement is what carries the worse visual outcomes (de-la-Torre 2026). We should be straight about the limit of this: we could not find a study reporting how often posterior uveitis presents with no pain at all, so we are not going to put a figure on it.

What people describe is vision degrading slowly enough that the other eye compensates. A detailed post in r/CrohnsDisease from someone with intermediate and posterior uveitis described exactly that: it crept up on one eye, the brain used the other, and by the time it was picked up they had lost useful sight in that eye (r/CrohnsDisease thread). Their practical suggestion, cover one eye occasionally and check that each one still sees properly, costs nothing and is not offered on any of the ranking pages we read. We are citing it as a sensible habit described by someone who lost vision, not as a tested screening method.

How much sight is at stake is genuinely hard to quantify honestly, and the numbers you will meet online are misleading. That same post repeated a widely circulated claim that uveitis is the third leading cause of blindness in the United States. We could not find the primary source for it, and we are not going to repeat a figure we cannot trace. What the literature does show is that in tertiary referral populations the outcomes can be poor: in a Colombian multicentre study of 1,716 people with non-infectious uveitis, 59.0% had some visual impairment and 30.0% met the definition of blindness, with panuveitis carrying the highest risk (de-la-Torre 2026). Those are people referred to seven specialist centres over twelve years in a setting with limited access to specialist care, so the figures describe the severe end of a referral pyramid, not the outlook for someone with a first episode of episodic anterior uveitis. Quoting them at a Crohn's reader without that context would be scaremongering.

Will an eye problem change my Crohn's treatment?

Most of the time, no, and the 2024 series is the only source we found that actually reports this.

Among 36 patients already on systemic therapy for IBD when eye inflammation appeared, therapy was left unchanged in 27, 75.0%. The split by type is the useful part: therapy changed in 5 of 30 anterior uveitis cases, 16.7%, and in 4 of 6 cases of posterior segment uveitis, scleritis or peripheral ulcerative keratitis, 66.7% (Arzbecker 2024). The arithmetic reconciles: 5 plus 4 is 9, and 36 minus 27 is 9.

So the honest answer to "will this mean changing my biologic" is that it depends entirely on where the inflammation is, which is another reason the slit lamp examination matters before anyone decides anything. Note also the design limits: this is one centre, retrospective, and 36 is a small denominator. It is the best available answer to a question patients ask constantly and nobody else reports.

On what actually treats these, an umbrella review of systematic reviews found only six reviews covering ocular manifestations at all. Anti-TNF agents were effective for most ocular cases, ustekinumab improved ocular symptoms in 55% to 59%, and the incidence of new ocular manifestations was 1% with both vedolizumab and ustekinumab. The authors' own conclusion was that the evidence across joints, skin and eyes is heterogeneous and of low quality, with certainty ranging from moderate to low (Nardone 2025). Read those response rates carefully: they are uncontrolled figures from observational series, and episcleritis in particular often settles on its own, so a 55% to 59% improvement rate with no comparison group cannot be attributed to the drug. There is no control arm to subtract, and that absence is the finding.

The anti-TNF paradox, and why the etanercept scare does not apply to you

You will find pages warning that anti-TNF drugs can cause uveitis. That is a real signal, and it is also mostly about a drug nobody with Crohn's is prescribed.

A registry study of two spontaneous reporting databases found 43 uveitis cases associated with etanercept, 14 with infliximab and 2 with adalimumab. After applying criteria to exclude patients whose underlying disease itself causes uveitis, the counts became 20, 4 and 2, and etanercept remained significantly over-represented (Lim 2007). A later review reached the same conclusion, that reported new-onset uveitis on anti-TNF therapy is predominantly under etanercept, while noting that its data came mainly from rheumatology because those drugs were used there longer, and that whether the link is real remains to be settled by better data (Nicolela Susanna 2020).

Here is the part the warning pages leave out. Etanercept does not work for Crohn's disease. In a randomised, double-blind, placebo-controlled trial of 43 patients, clinical response at week 4 was 39% on etanercept against 45% on placebo, a difference of nothing with a p value of 0.763, and the authors concluded it was safe but not effective (Sandborn 2001). Notice the shape of that result: a page quoting "39% of patients responded to etanercept" in isolation would sound encouraging, and the placebo arm did numerically better. Because of that trial, etanercept is not a Crohn's treatment, so the anti-TNF most implicated in causing uveitis is one a Crohn's patient will not be given. Reported cases for infliximab and adalimumab were far fewer, and both are used to treat uveitis.

Spontaneous reporting databases also have no denominator: they tell you how many reports were filed, not how often the event happens per patient treated. They cannot establish a rate, only a comparison between drugs within the same reporting system.

The best uveitis trial ever run excluded the uveitis most Crohn's patients get

This is worth knowing before you read anyone quoting it at you. The VISUAL I trial randomised 217 adults with active non-infectious uveitis to adalimumab or placebo, and found a hazard ratio of 0.50 for treatment failure with a 95% confidence interval of 0.36 to 0.70, with median time to failure of 24 weeks against 13 on placebo. Adverse events and serious adverse events were both more frequent on adalimumab, 1052.4 against 971.7 and 28.8 against 13.6 per 100 person-years. It was funded by AbbVie, the manufacturer (Jaffe 2016).

Now check the population. VISUAL I enrolled people with intermediate uveitis, posterior uveitis or panuveitis. Anterior uveitis was not included. And anterior uveitis is 90.5% of what the 2024 IBD series found (Arzbecker 2024). So the strongest randomised evidence for a biologic in uveitis was generated in the roughly one-in-ten presentation, not the nine-in-ten. That does not make the trial less good. It means "studied in uveitis" is not the same as "studied in the uveitis you have", and anyone quoting that hazard ratio at a Crohn's reader with a first episode of iritis is stretching it.

Does having one manifestation outside the gut predict another? The largest dataset says no

Almost every source on this topic states that one manifestation makes another more likely. The biggest study of the question found close to the opposite.

The Swiss uveitis analysis reported that uveitis was significantly associated with the onset of other extraintestinal manifestations in both Crohn's and colitis (Biedermann 2019), and the reviews repeat a version of it, with uveitis linked particularly to erythema nodosum and peripheral arthritis (Pytrus 2022).

Then a 2024 analysis assembled 12,083 IBD cases across four cohorts and reported that, contrary to previous reports, only 2% of subjects had multiple manifestations and most co-occurrences were negatively correlated (Khrom 2024). That is the same claim reversed against a much larger baseline. The same study found the strongest genetic signal for ocular manifestations of any category it measured, within the major histocompatibility complex, odds ratio 3.6 with a 95% confidence interval of 2.3 to 5.6. It also found manifestations overall more common in women, odds ratio 1.2, in Crohn's and especially colonic disease location, odds ratio 1.7, and in people who had needed surgery, odds ratio 1.7.

We cannot settle which is right. The larger study has the better baseline and the explicit contradiction; the Swiss analysis had longitudinal follow-up of a single national cohort. What we can say is that if someone tells you your joint pain means an eye problem is coming, the largest dataset available does not support that.

For context on the joint side of this, the risk runs both directions: in a population-based cohort of 4,101 people with ankylosing spondylitis, acute anterior uveitis reached a 20-year cumulative incidence of 24.5% with an adjusted hazard ratio of 15.5 against matched controls (Stolwijk 2015). That is a different population from yours, and we mention it only because IBD and spondyloarthritis overlap, not to transfer the figure.

Dry, gritty, sandy eyes: the most common complaint and the least useful evidence

This is what most people in the threads actually describe, and it is the part of the literature in the worst shape.

A case-control study compared 39 people with Crohn's, 26 with ulcerative colitis and 39 controls. Mean Ocular Surface Disease Index scores were 30.59 in Crohn's, 24.67 in colitis and 11.19 in controls, and the authors concluded Crohn's patients tend to develop dry eye disease more than colitis patients (Barta 2019). Two cautions. First, the colitis standard deviation of 23.48 against a mean of 24.67 means that distribution is nowhere near normal and the mean is a poor summary. Second, and more important, the authors themselves attributed the finding to immunosuppressant and anti-TNF use, not to the disease. The abstract does not give the numbers behind that, so we cannot check it.

On whether treating the gut helps the eye surface, the one piece of prospective data we found points the other way, and it is not in IBD patients. In 22 eyes of 22 people with Sjogren's syndrome secondary to various autoimmune diseases, systemic infliximab produced no significant change in tear film break-up time, Schirmer values, fluorescein staining or symptom scores at three or six months (Turkoglu 2015). That is a small, uncontrolled study in a different condition. It is enough to say that nobody should promise you a biologic will fix dry eyes; it is not enough to say it cannot.

Lubricating drops are the everyday answer and are available without a prescription. What matters is the boundary: gritty and annoying is a dry eye problem, while painful, light-sensitive or vision-affecting is not, and no quantity of artificial tears substitutes for someone examining the eye.

Night vision, vitamin A, and an arithmetic problem we could not resolve

There is a second, entirely separate route from Crohn's to an eye symptom, and it has nothing to do with inflammation in the eye: fat-soluble vitamin malabsorption.

Vitamin A is required for low-light vision. In a published case report, a 56-year-old man with Crohn's disease and pancreatitis was referred for severe dry eyes and had two years of blurred vision and poor night vision, with the characteristic surface changes of xerophthalmia in both eyes (Khan 2023). That is one person, in a country where the deficiency is rare, and a case report establishes that something can happen, not how often it does.

How often is where it gets difficult. A study of 38 Crohn's patients and 33 controls reported low serum retinol in 29% of patients against 15% of controls, and a positive relative dose response test, indicating inadequate liver stores, in 37% against 12%, both with P less than 0.005 (Soares-Mota 2015).

One more detail from that study cuts against the usual story: deficiency was not associated with ileal disease location, disease activity, or prior bowel resection. The textbook mechanism, ileal inflammation or resection causing fat-soluble vitamin malabsorption, was not what separated the deficient from the rest in this group. It was associated with lower BMI and lower body fat.

Do not act on this by buying vitamin A. High-dose vitamin A is genuinely toxic, the deficiency needs confirming on a blood test, and correcting it is a conversation with your IBD team, not a supermarket decision. If your night vision has changed, that is a symptom to report rather than a supplement to buy. Our guide to Crohn's disease hair loss goes through the same trap in more detail for iron and ferritin, where a normal-looking result can still be too low for the tissue that needs it.

The other half of the problem: the medications

Some eye findings in people with Crohn's are not the disease at all.

Corticosteroids are the main one. Reviews list cataract and glaucoma as direct consequences, plus diabetic retinopathy indirectly through raised blood sugar (Richardson 2024). There is a useful quantification from the eye side: in a retrospective cohort of 1,384 eyes with non-infectious scleritis and episcleritis managed at uveitis subspecialty centres, 76 developed cataract, an incidence of 0.025 per eye-year with a 95% confidence interval of 0.019 to 0.031. Oral corticosteroid use at the preceding visit, intraocular pressure at or above 30 mmHg, age 65 or over and anterior chamber inflammation all predicted it. Cataract surgery in those eyes improved median vision by six lines on a standard chart (Sun 2025). This study was funded by the National Eye Institute. Note what it says and does not say: the rate was low under subspecialty management, and steroid exposure was a predictor within that population, not a reason to change any treatment.

Steroid eye drops carry the same risks locally, which is the reason people in the threads report being moved off them deliberately once the inflammation settles rather than keeping a bottle in the drawer. Methotrexate is irritating to ocular tissues and is linked to conjunctivitis and lid inflammation (Richardson 2024).

Nothing here is a reason to stop or reduce a medication. It is a reason to mention an eye symptom to the person prescribing it, and to know that the answer might be about the drug rather than the disease. Our list of questions to ask your doctor about Crohn's disease includes a section on manifestations outside the gut if you want help structuring that conversation.

Should everyone with Crohn's have a routine eye examination? Three papers, three answers

This is a genuinely unsettled question, and the sources that sound most confident are the ones with the least data.

Yes, screen everyone. A review states that ophthalmic evaluation should be performed in all IBD patients (Pytrus 2022). A prospective study of 116 patients concluded eye examinations may be helpful as a routine part of follow-up (Yilmaz 2007). Both are recommendations, not trials of screening.

No firm recommendation possible. The paediatric systematic review looked specifically at screening studies: five studies, 357 asymptomatic children, and mild asymptomatic uveitis found in anywhere from 1.06% to 23.1% of them depending on the study. Crucially, no evidence of ocular complications from untreated uveitis was detected, and the long-term significance of these findings is unknown. The authors concluded that no recommendation on routine ophthalmological examination can be made, but that clinicians should keep a low threshold for referral (Ottaviano 2018).

That last finding is the one that decides the question for now. Screening asymptomatic people finds inflammation, but the only study set to look at what happens if you leave it found no complications. That is exactly the situation in which "screen everyone" is a hypothesis rather than a conclusion. The 23.1% upper bound also almost certainly comes from a small study; with 357 children across five studies, the individual denominators are not stated in the abstract and we could not check them.

Multidisciplinary care, whoever raises it. Every review on this topic lands on the same practical point: gastroenterology and ophthalmology working together, with a low threshold for sending someone across (Licona Vera 2023, Migliorisi 2024). That is not a screening protocol. It is a referral culture, and it is what to ask for.

What to track, so the pattern is visible instead of remembered

Eye episodes are short, scattered and easy to reconstruct wrongly. Six months later, "it happens when I flare" and "it happens randomly" feel identical from memory and look completely different on a dated list.

Four fields are enough:

A worked example of why this matters. Two people both report "my eye keeps going red". Person A has three episodes across eight weeks, each in the right eye, a tender pink patch on the white, no pain to speak of, vision normal, and each one lands during a week when their stool frequency and urgency had climbed. That pattern, unilateral, surface, recurrent, moving with the bowel, reads like episcleritis tracking disease activity, and the conversation is about bowel control as much as about the eye.

Person B has one episode that has lasted three weeks, aching behind the eye, hates bright rooms, sees a slight haze in that eye, and their calprotectin was low last month while they were doing well on a biologic. That does not fit episcleritis and it does not fit "nothing is wrong because my gut is fine". That is the presentation the reviews describe as running independently of bowel activity, and it belongs in front of an eye specialist quickly, not in a log waiting for the next appointment.

Neither of those is a diagnosis. Both are patterns that only exist if somebody wrote the dates down. If you already keep a gut log, adding an eye line to it costs almost nothing. Clairop logs symptoms with dates and produces a one-page summary for an appointment, which is the format that survives a short slot; our guide to taking a symptom tracker to your doctor covers what clinicians actually read and what gets ignored.

Myths worth retiring

"Crohn's affects the eyes because it is a connective tissue disease." This turns up in the threads and it is not right. Crohn's disease is an immune-mediated inflammatory bowel disease, not a connective tissue disorder. The mechanisms the reviews propose for eye involvement are immune dysregulation, antigens shared between gut and eye, genetic predisposition and circulating inflammatory signals (Migliorisi 2024), and the strongest genetic association found so far sits in the major histocompatibility complex (Khrom 2024). Getting the mechanism wrong matters because it leads people to expect the wrong doctors and the wrong tests.

"All Crohn's patients get uveitis." One person in a thread reported being told this by a gastroenterologist. Whatever was actually said, the figure is nowhere near that: 6% at enrolment in the Swiss cohort (Vavricka 2011), 3.2% confirmed by an eye specialist in a 1,320-patient chart review (Arzbecker 2024).

"If my eye is not painful, it cannot be serious." IBD-associated uveitis was described as frequently insidious in onset rather than sudden (Lyons 1997), and posterior involvement is what predicts the worse visual outcomes (de-la-Torre 2026). Pain is a useful alarm when it fires, not proof of anything when it does not.

"My gut is in remission, so this cannot be my Crohn's." For uveitis specifically, the reviews say the opposite: it commonly runs independently of bowel activity, and can even precede the IBD diagnosis (Richardson 2024).

"Eye problems mean my biologic is failing." Sometimes, but usually not. Three-quarters of patients on systemic therapy in the 2024 series had no change to therapy after eye inflammation appeared (Arzbecker 2024).

"Steroid eye drops are a safe long-term fix." They are effective short term, and they carry the same cataract and pressure risks as steroids elsewhere. Within the scleritis and episcleritis cohort, raised intraocular pressure and recent oral steroid exposure both predicted cataract (Sun 2025). This is a decision for the prescriber, not something to manage from a drawer.

When to see a doctor promptly

Contact an eye service or your IBD team the same day if:

• Vision has changed in any way: blurred, hazy, dimmer, a shadow, a curtain, or a new blind spot.
• There are new floaters or flashes of light.
• There is genuine pain in or behind the eye, particularly if it wakes you. Severe boring pain can indicate scleritis rather than episcleritis.
• Bright light is painful rather than just uncomfortable.
• A red eye is getting worse rather than better across two or three days, or has not settled within a week.

Mention it at your next appointment if: the eye is gritty, sandy or dry without pain or vision change; your lids are crusted or sore in the mornings; or redness comes and goes in patches without pain.

And the general Crohn's red flags still apply regardless of what your eyes are doing: blood in your stool, unexplained weight loss, fever, symptoms that wake you at night, new anaemia, or a sharp change from your usual pattern. See a doctor promptly for any of those.

If a symptom outside the gut arrives as part of a cluster, a red eye plus new joint swelling plus a new skin lesion plus mouth ulcers, report the cluster even if your bowels feel fine. Our guides to mouth ulcers with Crohn's disease and Crohn's disease brain fog cover two more symptoms that get raised late because they do not feel like gut problems, and the mouth ulcer guide also covers the Behcet's overlap, where recurrent oral ulcers and eye inflammation occur together and the distinction is a question for a clinician rather than a forum.

The honest bottom line

Crohn's disease can inflame your eyes. The most defensible figure available is single digits: 3.2% for uveitis in the one series where an eye specialist confirmed every case, though that was an IBD population rather than Crohn's alone. Much of what people actually describe is at the surface: dry, gritty, a tender red patch, uncomfortable rather than dangerous. A smaller number get inflammation inside the eye or into the eye wall, and that group needs seeing quickly, because glaucoma, macular swelling and permanent visual loss are on the table and that version does not always announce itself with pain.

What the literature will not give you is a clean number, a screening protocol, or a reliable rule connecting your eyes to your gut. The prevalence figures span two orders of magnitude depending on who counted. The classic description of IBD uveitis traces back to 17 patients in 1997 and the better-designed recent series found close to the opposite. The best randomised trial in uveitis excluded the type most Crohn's patients get. The largest genetic and clinical dataset reverses the widely repeated claim that one manifestation predicts another. And the only systematic look at screening asymptomatic people found inflammation it could not show mattered.

None of that is a reason to worry more. It is a reason to hold a simple rule instead of a statistic: anything involving pain, light or vision gets looked at by someone with a slit lamp, promptly, whatever your bowels are doing. Everything else goes in the log with a date, so that when someone finally asks whether your eyes follow your gut, you have an answer rather than an impression.